Necrobiotic Xanthogranuloma (NXG): Dermoscopic and Reflectance Confocal Microscopic Findings and Review of Treatment with Intravenous Immunoglobulin (IVIG) Authors: Zuzanna Pawlus, Irena Wojtowicz, Ewa Kaznowska, Adam Reich, Magdalena Żychowska Published: 2026 ABSTRACT Necrobiotic xanthogranuloma (NXG) is a rare, chronic non-Langerhans cell histiocytosis strongly associated with paraproteinemia and hematologic disorders. This study aims to present a clinical case of NXG, with particular emphasis on the dermoscopic and reflectance confocal microscopic (RCM) findings, and to review the literature on the efficacy of intravenous immunoglobulin (IVIG) therapy in this condition. A 58-year-old woman presented with progressive yellow-orange plaques, showing irregular vessels and hemorrhagic dots on dermoscopy. RCM displayed multiple large refractive cells and smaller cells with horseshoe-like structures, corresponding to xanthomatous histiocytes and Touton cells, respectively. Diagnostic evaluation revealed monoclonal IgG gammopathy and an indolent B cell lymphoma. Long-term treatment with IVIG combined with systemic glucocorticosteroids resulted in partial improvement. A review of 16 cases with follow-up available indicates that IVIG is a highly effective therapeutic option for NXG, often leading to rapid and significant improvement or complete remission. However, long-term responses vary, and interruption of therapy may result in disease relapse, suggesting the importance of sustained treatment. In conclusion, NXG is a multisystem disease showing several characteristics in noninvasive imaging methods. Although IVIG appears highly effective, variability in treatment response highlights the need for individualized management and for further research to better understand disease pathogenesis. Key Summary Points Necrobiotic xanthogranuloma (NXG) is a rare non-Langerhans cell histiocytosis strongly associated with paraproteinemia.Dermoscopy and confocal microscopy may provide additional clues suggestive of NXG.Confocal microscopy supports the visualization of foam cells and Touton multinucleated giant cells.Intravenous immunoglobulin (IVIG) therapy appears highly effective, often leading to rapid improvement or complete remission; however, the responses may vary.Prolonged therapy with IVIG may be necessary to maintain a good outcome. Necrobiotic xanthogranuloma (NXG) is a rare non-Langerhans cell histiocytosis strongly associated with paraproteinemia.Dermoscopy and confocal microscopy may provide additional clues suggestive of NXG.Confocal microscopy supports the visualization of foam cells and Touton multinucleated giant cells.Intravenous immunoglobulin (IVIG) therapy appears highly effective, often leading to rapid improvement or complete remission; however, the responses may vary.Prolonged therapy with IVIG may be necessary to maintain a good outcome. Introduction Necrobiotic xanthogranuloma (NXG) is a rare, chronic non-Langerhans cell histiocytosis characterized by firm yellow to red-orange nodules and plaques involving the skin. Lesions most commonly affect the periorbital region but may also occur at other cutaneous and extracutaneous sites [1], including the lungs, myocardium, larynx, pharynx, skeletal muscle, kidneys, ovaries, and intestines [2, 3]. NXG is strongly associated with paraproteinemia, although its pathogenesis remains unclear. Approximately 10% of patients develop multiple myeloma [1, 3]. The disease is usually slowly progressive and shows a poor therapeutic response. Current literature suggests that the most effective treatment options for NXG include intravenous immunoglobulins (IVIG) and systemic glucocorticosteroids, which are therefore considered first-line therapies in the affected patients. In a review by Steinhelfer et al., IVIG demonstrated very high response rates, with complete or partial remission observed in 81% of patients [4]. Despite this, follow-up data were not available for most cases, and long-term responses to IVIG therapy have not been analyzed to date. This paper presents a case of NXG treated with IVIG and high-dose systemic glucocorticosteroids, which resulted in a limited long-term clinical response. We also present videodermatoscopic and reflectance confocal microscopy (RCM) features of NXG lesions and provide a review of the literature on IVIG therapy in NXG. Case Report A 58-year-old woman was referred to the Department of Dermatology in September 2023 for evaluation of progressively enlarging yellow-orange skin lesions that had first appeared 1 year prior to admission. The eruptions were asymptomatic, initially involving the periocular area and subsequently extending to the neck and upper chest. The patient also reported an unintentional weight loss of approximately 15 kg over the preceding year. During that period, type 2 diabetes mellitus was diagnosed. On admission, physical examination revealed confluent yellow-orange plaques involving the periocular area, neck, and upper chest, with small necrotic foci on the eyelids (Fig. 1).Fig. 1Clinical presentation at initial visit in September 2023 Clinical presentation at initial visit in September 2023 Videodermoscopy revealed linear vessels on a yellow-orange background with clustered brown dots, observed under higher magnification (Fig. 2).Fig. 2a–c Videodermoscopic presentation of necrobiotic xanthogranuloma (NXG). a Videodermoscopy of the periorbital plaques showing irregular vessels and hemorrhagic dots (yellow arrows) on a yellow-orange-brown background. b, c Videodermoscopy of the plaques on the neck and chest showing thin linear branched vessels (blue arrows) and clustered brownish dots (red arrow) on a yellow background a–c Videodermoscopic presentation of necrobiotic xanthogranuloma (NXG). a Videodermoscopy of the periorbital plaques showing irregular vessels and hemorrhagic dots (yellow arrows) on a yellow-orange-brown background. b, c Videodermoscopy of the plaques on the neck and chest showing thin linear branched vessels (blue arrows) and clustered brownish dots (red arrow) on a yellow background Laboratory investigations performed during hospitalization showed mildly elevated inflammatory markers—erythrocyte sedimentation rate (ESR) of 49 mm/h (normal ≤ 10 mm/h) and a C-reactive protein (CRP) level of 3.3 mg/dL (normal ≤ 1 mg/dl), an increased serum C3 complement level, the presence of monoclonal IgG immunoglobulins in peripheral blood immunofixation (1 g/dl), and elevated serum free kappa light chains. RCM was performed and showed presence of single dendritic cells in the epidermis, disappearance of dermal papillae, scattered small inflammatory cells in the dermis, and multiple large medium-to-high refractive cells, which were vacuolated and resembled foam. In addition, smaller cells with horseshoe-like and flower-ring structures were noted. The last two types of cells most presumably corresponded to foam cells and Touton multinucleated giant cells, respectively (Fig. 3). In histopathology examination, normal epidermis and band-like aggregates of foamy histiocytes accompanied by multinucleated giant cells in the dermis were observed (Fig. 4). Although interstitial granuloma annulare was initially considered in histopathology, clinicopathological correlation together with monoclonal gammopathy established the diagnosis of NXG. In the differential diagnosis, xanthomas, necrobiosis lipoidica, amyloidosis, sarcoidosis, and foreign body granulomas were also considered.Fig. 3Reflectance confocal microscopy (RCM) of the periorbital plaques. a Single dendritic cells (yellow arrow) were present in the epidermis. b, c Multiple large medium-to-high refractive cells (green asterisks) corresponding to xanthomatous histiocytes, and smaller cells with horseshoe-like or flower-ring structures (red arrows) corresponding to Touton multinucleated cells were present in the dermis. Additionally, multiple scattered small bright inflammatory cells could be notedFig. 4Histopathological image showing normal epidermis and band-like infiltrates of histiocytes within the dermis, some with foamy cytoplasm, together with sparse multinucleated giant cells (hematoxylin & eosin staining) Reflectance confocal microscopy (RCM) of the periorbital plaques. a Single dendritic cells (yellow arrow) were present in the epidermis. b, c Multiple large medium-to-high refractive cells (green asterisks) corresponding to xanthomatous histiocytes, and smaller cells with horseshoe-like or flower-ring structures (red arrows) corresponding to Touton multinucleated cells were present in the dermis. Additionally, multiple scattered small bright inflammatory cells could be noted Histopathological image showing normal epidermis and band-like infiltrates of histiocytes within the dermis, some with foamy cytoplasm, together with sparse multinucleated giant cells (hematoxylin & eosin staining) Trephine biopsy of the bone marrow showed clusters of B cells of uncertain nature. Subsequent immunophenotyping of the bone marrow aspirate supported the presence of an indolent B cell lymphoma phenotypically most consistent with marginal zone lymphoma. At that time, there were no indications for systemic chemotherapy. Initially, before admission to the Department of Dermatology, the patient had been treated with topical corticosteroids and topical antibiotics. As a result of persistent disease, IVIG therapy was initiated in November 2023 at a dose of 2 g/kg body weight (administered over 3 days) at 4 weeks intervals. After sixth IVIG pulse in June 2024, the patient reported bilateral episodes of transient visual loss and dizziness. IVIG therapy was suspended from June to September 2024 during the diagnostic workup. Subsequently, large-vessel vasculitis with multilevel involvement of arteries arising from the aortic arch was diagnosed. During that time, prednisone 60 mg/day (1 mg/kg/day) and methotrexate 15 mg/week were introduced for large-vessel vasculitis. IVIG was resumed in September 2024 and subsequent cycles were administered regularly at monthly intervals, reaching the 23rd pulse in March 2026. Throughout this period, concomitant prednisone and methotrexate therapy was maintained. Prednisone therapy was gradually tapered to 50 mg/day in November 2024, 30 mg/day in January 2025, 17.5 mg/day in February 2025, 12.5 mg/day in March 2025, 10 mg/day in July 2025, and 7.5 mg/day in September 2025, which was maintained until the end of follow-up. Methotrexate was initially administered at a dose of 15 mg/week. In March 2025, the dose was increased to 17.5 mg/week and remained unchanged thereafter. The therapy resulted in a reduction of necrotic foci, as well as flattening and lightening of the lesions. However, the overall clinical improvement remained limited (Fig. 5).Fig. 5Clinical presentation of the patient after 23 cycles of intravenous immunoglobulins (IVIG) Clinical presentation of the patient after 23 cycles of intravenous immunoglobulins (IVIG) Methods We conducted a systematic search of the PubMed and Scopus databases using MeSH and EMTREE terms “necrobiotic xanthogranuloma” and “IVIG”. Case reports and case series published in English since the onset of the databases (the search period started from 1980 for PubMed and from 1970 for Scopus) until March 2026 were initially identified. After removing duplicates, studies were manually screened according to inclusion criteria, with independent review by co-authors to reduce bias. Reference lists of included papers were also screened. Only cases involving IVIG treatment were included in the analysis. Reports not presenting the details of IVIG treatment or without follow-up were excluded. In total, 22 articles were initially identified, of which 14 reports met the criteria. Two of the studies included descriptions of two patients each, resulting in a total of 16 patient cases analyzed (Fig. 6, PRISMA flowchart). The data collected include patient demographics (age, sex, country), affected body regions, duration of symptoms prior to hospital admission, the morphology and distribution of the lesions, coexisting malignancies, previous treatments, the IVIG treatment regimen applied, and IVIG treatment response.Fig. 6PRISMA flow diagram presenting the details of the search and selection process for case reports describing the use of IVIG treatment in patients with necrobiotic xanthogranuloma (NXG) PRISMA flow diagram presenting the details of the search and selection process for case reports describing the use of IVIG treatment in patients with necrobiotic xanthogranuloma (NXG) Written informed consent was obtained from the patient to participate, to publish the article, and for use of their photos. Results Table 1 presents the papers included in the review.Table 1Summary of the case reports and case series on the use of intravenous immunoglobulins (IVIG) treatment in patients with necrobiotic xanthogranuloma (NXG)Author, year and countryAge/sexDuration of symptoms prior to hospital admissionHematological or internal malignanciesPrevious dermatological or hematological treatmentIVIG treatment regimenResponse to IVIG treatmentHallermann et al., 2010, Germany; case 1 [5]55/W9 yearsMGUS (IgG-gamma)Topical steroids, psoralen–UV-A with high-dose UV-A1, chloroquine, hydroxychloroquine, cyclosporine A, acitretin, ceftriaxone, extracorporeal photopheresisIVIG—2 g/kg (administered over 4 days) at 4-week intervals (interval was extended to 8 weeks), total 10 cyclesAlmost complete regression of the lesions in most sites. The level of free gamma light chains in the serum did not decrease during the treatmentHallermann et al., 2010, Germany; case 2 [5]69/W5 yearsMultiple myelomaIntravenous and oral prednisolone, clofazimine, UVA1, dapsone, minocycline, interferon alfa-2a, and mycophenolate mofetil, all without clinically significant effectIVIG—2 g/kg (administered over 4 days) at 4-week intervals (interval was extended to 12 weeks), total 11 cyclesElevated margins of the skin lesions, induration, and erythematous color decreased substantially after the first 2 cycles and continued improving with successive cycles. An initially increased level of total kappa light chains normalized within the first months of treatment. A biopsy specimen obtained from a residual upper-arm lesion after the fifth IVIG treatment cycle showed almost complete resolution of the infiltratesZiemer et al., 2012, Germany [6]55/W9 yearsMGUS (IgG-lambda)Topical steroids, psoralen–ultraviolet A phototherapy, cyclosporine A, chloroquine, hydroxychloroquine, acitretin, ceftriaxone, and extracorporeal photopheresisIVIG—2 g/kg (administered over 4 days) at 4-week intervals (interval was extended to 8 weeks)Plaques continuously decreased in thickness and induration and the coloration became paler. After 6 cycles of IVIG, a biopsy of the residual pale erythema revealed a complete resolution of the infiltrateRubinstein et al., 2013, USA [7]68/W7 yearsMGUS (IgG-kappa)Intralesional injection of triamcinolone, multidrug chemotherapy, (melphalan, lenalidomide, and bortezomib) in combination with corticosteroidsIVIG 45 g twice at a 3-week intervals, total 29 cyclesRegression of cutaneous nodules, particularly in the postauricular areas after first infusion. Discontinuation of IVIG led to progression of the lesions after a few weeks while resumption of treatment again led to regression. Following the onset of IVIG therapy, the serum monoclonal IgG(κ) persisted without a significant change in concentrationLiszewski et al. 2014, USA; case 1 [8]39/W2 yearsNo monoclonal gammopathyChlorambucil, methotrexate, acitretin, electron beam therapy, infliximab, thalidomide, and extracorporeal photopheresisIVIG—2 g/kg (administered over 4 days) at 4-week intervalsDramatic improvement in lesion size and colorLiszewski et al., 2014, USA; case 2 [8]60/W1 yearMGUS (IgG-kappa)Methotrexate with acitretin, cyclophosphamide, and lenalidomide with dexamethasoneIVIG—2 g/kg (administered over 4 days) at 4-week intervalsLesion improvement was noted after the first infusionPedrosa et al., 2015, USA [9]44/W1 yearMGUS (IgG-kappa) and giant cell hepatitisOral prednisolone and oral budesonideIVIG—2 g/kg (administered over 4 days) at 4-week intervals (after 15 cycles, interval was extended to 8 weeks), total 18 cyclesAfter 3 cycles of IVIG the skin lesions improved remarkablyNambudiri et al., 2016, USA [10]61/M30 yearsMGUS (IgG-kappa)Intralesional and systemic corticosteroids, chlorambucil and thalidomide, cryotherapy, surgical excision, methotrexate, chlorambucil, thalidomide, intralesional triamcinolone, fractional laser therapyIVIG in a combination with electron beam radiation (10–15 Gy using a 6 MeV electron beam)Significant improvementLukáács et al., 2017, Germany [11]74/WN/AIgM kappa monoclonal gammopathyTopical clobetasol propionateIVIG—2 g/kg (administered over 4 days) at 4-week intervals, total 4 cyclesLesion improvement was noted after the second cycle. Beneficial response was achieved after 4 IVIG cycles—treatment resulted in flattening of the periorbital lesionsOlson et al., 2018, Brazil [12]44/W2 yearsMultiple myelomaCyBorD (cyclophosphamide, bortezomib, and dexamethasone) with subcutaneous bortezomibIVIG—2 g/kg (administered over 4 days) at 4-week intervals, total 16 cyclesImprovement after 3 cycles. After 9 cycles, there was dramatic improvement. By cycle 16, all previously noted lesions were resolvedGoyal et al., 2019, USA [13]42/W1.5 yearMGUS (IgG-kappa)Rituximab, RCVP (rituximab, cyclophosphamide, vincristine, and prednisolone), CyBorD (cyclophosphamide, bortezomib, and dexamethasone), and mycophenolate mofetilIVIG—2 g/kg (administered over 4 days) at 4-week intervalsAfter the second cycle of IVIG the patient noted decreased periocular pain. By fifth cycle a dramatic improvement in periorbital plaques with near-complete resolution was notedDellatorre et al., 2020, Brazil [14]40/W8 yearsMGUS (IgG-kappa)Thalidomide and corticosteroidsIVIG for 9 monthsStabilization was only temporary before progressionPortuguese et al., 2021, USA [15]75/W2 yearsSmoldering myelomaCorticosteroids, ultraviolet B phototherapy, lenalidomide + dexamethasone, bortezomib + dexamethasone, ixazomib + dexamethasone, pomalidomide + dexamethasoneIVIG—1 g/kg at 4-week intervalsWell tolerated and extremely effectiveShahriari et al., 2023, USA [16]64/WN/AMGUS (IgG-kappa)Prednisone, azathioprine, infliximab, mycophenolate mofetil, and intralesional triamcinolone acetonideIVIG—2 g/kg80% improvement of lesions characterized by thinning and shrinking of plaques after IVIG. However, after 9 months, the patient noted the persistence of a plaque on the right temple complicated by ulceration and preseptal cellulitis, the lesion remained recalcitrantWinkler et al., 2024, Germany [17]57/MN/ASmoldering myelomaDapsone, tacrolimus, and adalimumabIVIG—2 g/kg (administered over 4 days) at 4-week intervalsAfter 3 cycles of IVIG visible improvement of skin lesions, dramatic improvement after 6 monthsGilbert-Falardeau et al., 2024, Canada [18]92/WMore than 10 yearsMultiple myelomaIntralesional triamcinoloneIVIG—2 g/kg (administered over 4 days) at 4-week intervals, total 7 cyclesAfter 7 cycles, there was complete resolution of the lesions and IVIG was discontinued. Five months after treatment discontinuation (12 months after starting IVIG), the patient was still in remissionThis case58/W4 yearsIndolent peripheral B cell lymphomaTopical corticosteroids and topical antibioticsIVIG—2 g/kg (administered over 3 days) at 4-week intervals (total 23 cycles) with high-dose systemic glucocorticosteroids (60 mg daily with gradual dose reduction)A reduction of necrotic foci, as well as flattening and lightening of the lesions; however, the overall clinical improvement remained limitedW woman, M man, MGUS monoclonal gammopathy of undetermined significance, N/A not available Table 1Summary of the case reports and case series on the use of intravenous immunoglobulins (IVIG) treatment in patients with necrobiotic xanthogranuloma (NXG)Author, year and countryAge/sexDuration of symptoms prior to hospital admissionHematological or internal malignanciesPrevious dermatological or hematological treatmentIVIG treatment regimenResponse to IVIG treatmentHallermann et al., 2010, Germany; case 1 [5]55/W9 yearsMGUS (IgG-gamma)Topical steroids, psoralen–UV-A with high-dose UV-A1, chloroquine, hydroxychloroquine, cyclosporine A, acitretin, ceftriaxone, extracorporeal photopheresisIVIG—2 g/kg (administered over 4 days) at 4-week intervals (interval was extended to 8 weeks), total 10 cyclesAlmost complete regression of the lesions in most sites. The level of free gamma light chains in the serum did not decrease during the treatmentHallermann et al., 2010, Germany; case 2 [5]69/W5 yearsMultiple myelomaIntravenous and oral prednisolone, clofazimine, UVA1, dapsone, minocycline, interferon alfa-2a, and mycophenolate mofetil, all without clinically significant effectIVIG—2 g/kg (administered over 4 days) at 4-week intervals (interval was extended to 12 weeks), total 11 cyclesElevated margins of the skin lesions, induration, and erythematous color decreased substantially after the first 2 cycles and continued improving with successive cycles. An initially increased level of total kappa light chains normalized within the first months of treatment. A biopsy specimen obtained from a residual upper-arm lesion after the fifth IVIG treatment cycle showed almost complete resolution of the infiltratesZiemer et al., 2012, Germany [6]55/W9 yearsMGUS (IgG-lambda)Topical steroids, psoralen–ultraviolet A phototherapy, cyclosporine A, chloroquine, hydroxychloroquine, acitretin, ceftriaxone, and extracorporeal photopheresisIVIG—2 g/kg (administered over 4 days) at 4-week intervals (interval was extended to 8 weeks)Plaques continuously decreased in thickness and induration and the coloration became paler. After 6 cycles of IVIG, a biopsy of the residual pale erythema revealed a complete resolution of the infiltrateRubinstein et al., 2013, USA [7]68/W7 yearsMGUS (IgG-kappa)Intralesional injection of triamcinolone, multidrug chemotherapy, (melphalan, lenalidomide, and bortezomib) in combination with corticosteroidsIVIG 45 g twice at a 3-week intervals, total 29 cyclesRegression of cutaneous nodules, particularly in the postauricular areas after first infusion. Discontinuation of IVIG led to progression of the lesions after a few weeks while resumption of treatment again led to regression. Following the onset of IVIG therapy, the serum monoclonal IgG(κ) persisted without a significant change in concentrationLiszewski et al. 2014, USA; case 1 [8]39/W2 yearsNo monoclonal gammopathyChlorambucil, methotrexate, acitretin, electron beam therapy, infliximab, thalidomide, and extracorporeal photopheresisIVIG—2 g/kg (administered over 4 days) at 4-week intervalsDramatic improvement in lesion size and colorLiszewski et al., 2014, USA; case 2 [8]60/W1 yearMGUS (IgG-kappa)Methotrexate with acitretin, cyclophosphamide, and lenalidomide with dexamethasoneIVIG—2 g/kg (administered over 4 days) at 4-week intervalsLesion improvement was noted after the first infusionPedrosa et al., 2015, USA [9]44/W1 yearMGUS (IgG-kappa) and giant cell hepatitisOral prednisolone and oral budesonideIVIG—2 g/kg (administered over 4 days) at 4-week intervals (after 15 cycles, interval was extended to 8 weeks), total 18 cyclesAfter 3 cycles of IVIG the skin lesions improved remarkablyNambudiri et al., 2016, USA [10]61/M30 yearsMGUS (IgG-kappa)Intralesional and systemic corticosteroids, chlorambucil and thalidomide, cryotherapy, surgical excision, methotrexate, chlorambucil, thalidomide, intralesional triamcinolone, fractional laser therapyIVIG in a combination with electron beam radiation (10–15 Gy using a 6 MeV electron beam)Significant improvementLukáács et al., 2017, Germany [11]74/WN/AIgM kappa monoclonal gammopathyTopical clobetasol propionateIVIG—2 g/kg (administered over 4 days) at 4-week intervals, total 4 cyclesLesion improvement was noted after the second cycle. Beneficial response was achieved after 4 IVIG cycles—treatment resulted in flattening of the periorbital lesionsOlson et al., 2018, Brazil [12]44/W2 yearsMultiple myelomaCyBorD (cyclophosphamide, bortezomib, and dexamethasone) with subcutaneous bortezomibIVIG—2 g/kg (administered over 4 days) at 4-week intervals, total 16 cyclesImprovement after 3 cycles. After 9 cycles, there was dramatic improvement. By cycle 16, all previously noted lesions were resolvedGoyal et al., 2019, USA [13]42/W1.5 yearMGUS (IgG-kappa)Rituximab, RCVP (rituximab, cyclophosphamide, vincristine, and prednisolone), CyBorD (cyclophosphamide, bortezomib, and dexamethasone), and mycophenolate mofetilIVIG—2 g/kg (administered over 4 days) at 4-week intervalsAfter the second cycle of IVIG the patient noted decreased periocular pain. By fifth cycle a dramatic improvement in periorbital plaques with near-complete resolution was notedDellatorre et al., 2020, Brazil [14]40/W8 yearsMGUS (IgG-kappa)Thalidomide and corticosteroidsIVIG for 9 monthsStabilization was only temporary before progressionPortuguese et al., 2021, USA [15]75/W2 yearsSmoldering myelomaCorticosteroids, ultraviolet B phototherapy, lenalidomide + dexamethasone, bortezomib + dexamethasone, ixazomib + dexamethasone, pomalidomide + dexamethasoneIVIG—1 g/kg at 4-week intervalsWell tolerated and extremely effectiveShahriari et al., 2023, USA [16]64/WN/AMGUS (IgG-kappa)Prednisone, azathioprine, infliximab, mycophenolate mofetil, and intralesional triamcinolone acetonideIVIG—2 g/kg80% improvement of lesions characterized by thinning and shrinking of plaques after IVIG. However, after 9 months, the patient noted the persistence of a plaque on the right temple complicated by ulceration and preseptal cellulitis, the lesion remained recalcitrantWinkler et al., 2024, Germany [17]57/MN/ASmoldering myelomaDapsone, tacrolimus, and adalimumabIVIG—2 g/kg (administered over 4 days) at 4-week intervalsAfter 3 cycles of IVIG visible improvement of skin lesions, dramatic improvement after 6 monthsGilbert-Falardeau et al., 2024, Canada [18]92/WMore than 10 yearsMultiple myelomaIntralesional triamcinoloneIVIG—2 g/kg (administered over 4 days) at 4-week intervals, total 7 cyclesAfter 7 cycles, there was complete resolution of the lesions and IVIG was discontinued. Five months after treatment discontinuation (12 months after starting IVIG), the patient was still in remissionThis case58/W4 yearsIndolent peripheral B cell lymphomaTopical corticosteroids and topical antibioticsIVIG—2 g/kg (administered over 3 days) at 4-week intervals (total 23 cycles) with high-dose systemic glucocorticosteroids (60 mg daily with gradual dose reduction)A reduction of necrotic foci, as well as flattening and lightening of the lesions; however, the overall clinical improvement remained limitedW woman, M man, MGUS monoclonal gammopathy of undetermined significance, N/A not available Summary of the case reports and case series on the use of intravenous immunoglobulins (IVIG) treatment in patients with necrobiotic xanthogranuloma (NXG) W woman, M man, MGUS monoclonal gammopathy of undetermined significance, N/A not available The majority of patients were female, and most cases were associated with underlying hematological disorders, particularly monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). The duration of symptoms prior to treatment of NXG varied considerably, ranging from 1 year to more than 10 years. Clinically, lesions most frequently involved the periorbital region, although spreading to the trunk and extremities was common. IVIG was administered in all presented cases, most commonly at a dose of 2 g/kg per cycle divided over 3–4 consecutive days at 4-week intervals. In several reports, treatment intervals were extended following initial improvement, while in others therapy was continued long-term. The total number of cycles varied widely, from 4 to 29, reflecting both disease chronicity and the need for sustained treatment. Overall, IVIG therapy demonstrated a high rate of clinical efficacy. Rapid improvement within the first 1–3 treatment cycles was observed in most patients (12 of 16 reported cases, 75%), including reduction in lesion size, induration, and erythema, as well as flattening and lightening of plaques. In a substantial proportion of cases, this response progressed to near-complete or complete resolution of lesions, sometimes accompanied by histopathological clearance of inflammatory infiltrates. Continued IVIG therapy was frequently associated with sustained remission, whereas treatment discontinuation in some cases led to relapse, with subsequent reintroduction resulting in renewed clinical improvement. Notably, therapeutic benefit was observed regardless of the presence of concomitant hematological disease, although paraproteinemia often persisted despite cutaneous improvement. However, not all patients responded equally well. A minority of cases demonstrated partial, transient, or limited responses, indicating variability in treatment efficacy. In comparison, the present case showed only a modest therapeutic effect, despite the administration of IVIG therapy in combination with systemic glucocorticosteroids. A reduction of necrotic foci and partial improvement in lesion morphology was obtained; however, the overall clinical response remained limited despite prolonged treatment (23 cycles). While improvement was observed after initial cycles, the disease progressed during a temporary interruption of therapy, suggesting only partial response. Contrary to reports in the literature, long-term administration of IVIG did not result in a considerable remission. Discussion Necrobiotic xanthogranuloma (NXG) is a rare, chronic non-Langerhans cell histiocytosis, first described by Kossard and Winkelmann in 1980 [19]. The disease mostly affects patients in the sixth decade of life with no gender preference [4]. A hallmark of NXG is its strong association with paraproteinemia and hematologic disorders [4]. Large cohort analyses have demonstrated that up to 83.8% of patients present with monoclonal gammopathy and/or hematologic malignancy, most commonly IgG-κ type, while multiple myeloma is diagnosed in approximately 10–14% of cases [2, 3, 12]. It has been proposed that monoclonal immunoglobulins form complexes with lipids and deposit in tissues, triggering a foreign-body giant cell reaction [5, 20]. Alternatively, paraproteins may function as autoantibodies, promoting macrophage activation and granuloma formation, or interact with lipoprotein receptors, leading to lipid accumulation and xanthomatous changes [2, 20]. Importantly, progression from monoclonal gammopathy to overt malignancy may occur several years after the onset of cutaneous lesions [2]. In addition to hematologic malignancies, cancers of internal organs, e.g., liver malignancy, may also occur [9]. No characteristics of NXG have been found to predict disease course or severity [12]. Clinically, NXG presents with yellowish to orange-brown papules, nodules, or plaques [4]. The periorbital region is the most characteristic and frequently involved site, although lesions may extend to the trunk and extremities [20]. Cutaneous lesions may be accompanied by pain (30.7%) and pruritus (17%) [2, 21]. Importantly, extracutaneous manifestations may occur in various organs [2, 5]. Large-vessel vasculitis in association with NXG, such as in the case presented here, has also been reported in the literature [22]. NXG should be distinguished from conditions such as necrobiosis lipoidica, granuloma annulare (including interstitial variants), sarcoidosis, diffuse normolipemic plane xanthomas, xanthelasma, mycosis fungoides, scleromyxedema, and infectious granulomatous diseases [6, 20, 21]. Typical histopathological features include palisading granulomas with areas of necrobiosis, dense infiltrates of foamy histiocytes, lymphocytes, and plasma cells, as well as the presence of Touton-type and foreign-body giant cells [2, 5, 6]. Cholesterol clefts are considered a hallmark finding, although not universally present [4, 6]. Early lesions of NXG may closely resemble granuloma annulare. This highlights the importance of clinicopathological correlation and, when necessary, repeated biopsy. (Video)dermoscopy and RCM represent noninvasive real-time imaging methods that are gaining importance in preliminary diagnosis and treatment-monitoring of non-neoplastic skin conditions. While reviewing the literature, we came across one report of dermoscopic features of NXG [23] and no descriptions of the RCM findings in this entity. Miola et al. reported a case of NXG in a patient with Pelger-Huët anomaly, in which dermoscopy showed irregularly distributed teleangiectasia over yellow background. RCM has been demonstrated to have a supportive role in the diagnosis of juvenile and adult xanthogranuloma, by showing highly refractive giant cells with distinct nuclei, corresponding to Touton multinucleated giant cells [24–28]. In many cases, the primary differential diagnosis for NXG is xanthelasma. In the latter case, RCM rarely reveals presence of small inflammatory cells or highly refractive cells with distinct horseshoe-like or disc-like nuclei, and when it does, it is in very small numbers [29]. Therefore, noninvasive imaging methods such as RCM can provide diagnostic clues helpful in the initial differentiation from other orange-yellowish plaques (e.g., xanthelasma) or, by visualizing multinucleated giant cells, in the selection of a biopsy site. Numerous systemic therapies including corticosteroids, alkylating agents, immunomodulators, and biologics have been used in the treatment of NXG with variable and often unsatisfactory outcomes [4]. In recent years, IVIG has emerged as one of the most promising options [5]. While IVIG therapy is expensive, it is generally well tolerated, and its adverse effects are rare and easily managed [8, 11]. The main adverse event during the loading dose period is headache. Another benefit of IVIG is that it can be a useful and safe alternative for refractory NXG, including in women of childbearing age [9]. High-dose IVIG exerts broad immunoregulatory, anti-inflammatory, and immunosuppressive effects, making it beneficial in various autoimmune and inflammatory conditions [12]. Although the exact mechanisms of IVIG in NXG remain unclear, evidence from other immune-mediated diseases suggests that IVIG exerts broad immunomodulatory and anti-inflammatory effects. These include neutralization of pathogenic antibodies, modulation of B cell and T cell activity, regulation of Fc receptor signaling and cytokine networks, inhibition of complement activation, and reduction of macrophage-mediated inflammation [5, 30]. Despite these encouraging results, treatment response is not uniform. Cases of partial, transient, or refractory responses have been reported, highlighting significant interindividual variability. In a case report described by Rubinstein et al., discontinuation of IVIG therapy led to lesion progression within a few weeks, while restarting the treatment resulted in lesion regression [7]. Our case reflects a less favorable scenario, with only modest improvement after 23 cycles. It also emphasizes the need for prolonged therapy to maintain the effect. Several factors may contribute to variability of treatment response, including disease duration, extent of systemic involvement, and underlying hematologic conditions. Interestingly, improvement of cutaneous lesions does not necessarily correlate with changes in paraproteinemia, and treatment of the underlying hematologic disorder may not always lead to dermatologic improvement [8]. It is also important to acknowledge potential publication bias, as successful cases are more likely to be reported, potentially overestimating the efficacy of IVIG [1]. Additionally, the absence of standardized severity scales and outcome measures further complicates the assessment of treatment response and comparison across studies. From a safety perspective, IVIG is generally well tolerated, with a low incidence of serious adverse events, making it suitable for long-term use [2, 30, 31]. This is particularly relevant when compared to systemic corticosteroids, which carry significant long-term risks [17]. However, IVIG remains an off-label therapy for NXG, and further studies in larger patient cohorts are needed to better define its role and identify predictors of response. Conclusions NXG is a complex multisystem disorder that requires a multidisciplinary diagnostic and therapeutic approach. Although IVIG appears to be one of the most effective treatment options, often leading to rapid and sustained clinical improvement, the present case, as well as available literature, demonstrates significant heterogeneity in treatment response. Authors should be encouraged to report all cases, regardless of treatment success, to enable a more accurate evaluation of therapeutic options.